Navigation Links
Palatin Technologies to Report Fiscal Year 2009 First Quarter Results; Conference Call and Webcast on November 17, 2008
Date:11/13/2008

CRANBURY, N.J., Nov. 13 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (Amex: PTN) will announce its first quarter, fiscal year 2009 financial results on Monday, November 17, 2008 before the open of the U.S. financial markets.

The Company will also conduct a conference call and live audio webcast hosted by Palatin's executive management team on November 17, 2008 at which they will discuss the results of operations in greater detail and provide an update on corporate developments.

Schedule for the Financial Results Press Release, Conference Call and Webcast

-- Q1-Fiscal Year 2009 Financial Results

Press Release 11/17/2008 at 7:30 a.m. ET

-- Q1-Fiscal Year 2009 Conference Call - Live 11/17/2008 at 11:00 a.m. ET

Domestic Dial-In Number 1-888-263-2919

International Dial-In Number 1-913-312-0381

Passcode: 7115648

-- Q1-Fiscal Year 2009

Conference Call -- Replay 11/17-11/24/2008

Domestic Dial-In Number 1-888-203-1112

International Dial-In Number 1-719-457-0820

Replay Passcode: 7115648

-- Webcast Live and Replay Access http://www.palatin.com

The webcast and replay can be accessed by logging on to the "Investor/Media Center-Webcasts" section of Palatin's website at http://www.palatin.com.

About Palatin Technologies, Inc.

Palatin Technologies, Inc. is a biopharmaceutical company dedicated to the development of peptide, peptide mimetic and small molecule compounds with a focus on melanocortin and natriuretic peptide receptor systems. The melanocortin system is involved in a large and diverse number of physiologic functions, and therapeutic agents modulating this system may have the potential to treat a variety of conditions and diseases, including sexual dysfunction, obesity and related disorders, ischemia-reperfusion injury, hemorrhagic shock and inflammation-related diseases. The natriuretic peptide receptor system has numerous cardiovascular functions, and therapeutic agents modulating this system may be useful in treatment of heart failure, hypertension and other cardiovascular diseases. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential. For additional information regarding Palatin, please visit Palatin Technologies' website at http://www.palatin.com.


'/>"/>
SOURCE Palatin Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Palatin Technologies, Inc. Revised Call-In Number for Teleconference and Webcast to be held on September 30, 2008
2. Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
3. Palatin Technologies Announces New Strategic Objectives and Reports Third Quarter 2008 Financial Results
4. Palatin Technologies to Report Third Quarter, Fiscal Year 2008 Financial Results; Teleconference and Webcast on May 13th
5. Palatin Technologies, Inc. Reports Positive Results of a Phase I Clinical Study With PL-3994 for the Treatment of Congestive Heart Failure
6. Palatin Technologies to Report Second Quarter, Fiscal Year 2008 Financial Results; Teleconference and Webcast on February 11th
7. Palatin Technologies, Inc. Reports Fiscal Year 2008 First Quarter Results; Teleconference and Webcast to be Held on November 9, 2007
8. Palatin Technologies to Report Fiscal Year 2008 First Quarter Results; Teleconference and Webcast on November 9, 2007
9. Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2007 Results; Teleconference and Webcast to be held on September 18, 2007
10. Palatin Technologies Refutes Competitive Technologies Contention of Material Breach
11. Palatin Technologies Announces Reacquisition of Full Rights to Bremelanotide Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... -- Lexus, a returning partner of the Amgen Tour of California ... partner of the men,s and women,s events for the next five ... Tour of California will mark the start ... professional cycling teams in the world racing from Northern to ... Breakaway from Heart Disease TM Women,s Race empowered with ...
(Date:2/21/2017)... Research and Markets has announced the addition of the ... Forecast to 2025" report to their offering. ... The Global Bioplastics & Biopolymers ... over the next decade to reach approximately $8.9 billion by 2025. ... forecasts for all the given segments on global as well as ...
(Date:2/20/2017)... , Feb. 20, 2017 This report analyzes ... the following Product Types: Xylanase, Amylase, Cellulase, and Others. The ... Canada , Japan , ... Latin America , and Rest of World. ... Annual estimates and forecasts are provided for the period 2015 ...
(Date:2/20/2017)... ... February 20, 2017 , ... ... prevent chest wall collapses in pre-term infants with respiratory distress, and assist ... of $600,000 in funding through the ninth round of the University City ...
Breaking Biology Technology:
(Date:1/24/2017)... -- It sounds simple and harmless—an electronic sensor attached ... and alerts parents on their smart phones if, ... But pediatric experts argue that such devices may ... of medical benefits, especially to healthy babies. ... of healthy babies, promising peace of mind about ...
(Date:1/21/2017)... Research and Markets has announced the addition ... to their offering. ... The global voice recognition biometrics market to grow at a ... report covers the present scenario and the growth prospects of the ... size, the report considers the revenue generated from the sales of ...
(Date:1/19/2017)... SANTA CLARA, Calif. , Jan. 19, 2017 ... Valley company enhancing user experience and security for ... provider of next-generation payment processing systems and cybersecurity ... assist more banks, enterprises and financial institutions worldwide ... As part of the end-to-end secure user authentication ...
Breaking Biology News(10 mins):